Winlevi (Clascoterone) for Acne: The Complete Guide

What Is Winlevi (Clascoterone)?

Winlevi is the brand name for clascoterone cream 1% — the first and only FDA-approved topical anti-androgen for acne. Approved in August 2020 for patients 12 years and older, it represents a genuinely new class of acne treatment. Every other topical acne medication works on cell turnover (retinoids), bacteria (benzoyl peroxide), or inflammation (antibiotics). Winlevi is the first topical that addresses the hormonal driver of acne — the androgen receptor.

Before Winlevi, the only way to block androgen receptors for acne was through systemic medications: oral spironolactone or combination birth control pills. Both work, but both affect androgen receptors throughout the entire body — causing side effects from breast tenderness to potassium imbalances to menstrual disruption. Winlevi proved that you could block the receptor at the skin without systemic consequences.

Winlevi is manufactured by Sun Pharmaceutical Industries and requires a prescription. It's applied twice daily to affected areas. The active ingredient, clascoterone (also called cortexolone 17α-propionate), competes with DHT for androgen receptors in the sebaceous gland. Once it binds, it's hydrolysed locally in the skin to cortexolone — an inactive metabolite — meaning virtually none of the drug reaches systemic circulation.

How Winlevi Works: The Anti-Androgen Mechanism

Winlevi's mechanism is the same one that makes spironolactone so effective for hormonal acne — androgen receptor blocking. The difference is the delivery: topical instead of oral.

What the Clinical Trials Actually Show

Winlevi was approved based on two phase III randomised, double-blind, vehicle-controlled clinical trials involving over 1,400 patients aged 12 and older with moderate-to-severe acne. Here's what the data actually showed — including the numbers most articles skip.

Let's put those numbers in context. An 18-20% treatment success rate might sound low, but this is using the FDA's strict IGA (Investigator Global Assessment) criteria which requires near-complete clearing. In real-world practice, many more patients experience meaningful improvement that doesn't meet the binary "success" threshold. The ~40% inflammatory lesion reduction and ~30% non-inflammatory lesion reduction at 12 weeks are clinically meaningful and continued to improve with ongoing use.

However, there are important limitations. The trials included all acne types (not just hormonal), which likely diluted Winlevi's results for the specific population it's designed to help. Patients with primarily hormonal, androgen-driven acne would be expected to respond better than patients with comedonal or primarily bacterial acne where the androgen pathway isn't the primary driver. No sub-analysis by hormonal acne status has been published.

The trials also didn't compare Winlevi to any active treatment — only to vehicle (placebo) cream. There are no head-to-head studies against spironolactone, tretinoin, or benzoyl peroxide. The AAD conditionally recommends Winlevi but notes that comparative data are needed to justify its use over less expensive alternatives.

Who Is Winlevi Best For?

Winlevi occupies a specific niche in acne treatment. It's not the best option for everyone — but for certain patients, it fills a gap that no other treatment can.

Winlevi Side Effects: The Full Picture

Winlevi's safety profile is one of its strongest advantages. In clinical trials involving 722 patients receiving clascoterone, side effects were mild, localised, and occurred at rates similar to the vehicle (placebo) cream.

What Winlevi does NOT cause (compared to oral spironolactone): no diuretic effect, no breast tenderness, no menstrual irregularity, no potassium elevation, no dizziness, no fatigue. A small number of trial participants showed laboratory findings of HPA axis suppression and hyperkalemia, but none were clinically significant. This is the advantage of local metabolism — the drug never reaches meaningful systemic levels.

The Cost Problem: Why Most Patients Can't Access Winlevi

This is the elephant in the room. Winlevi's science is sound. Its mechanism is exactly what hormonal acne patients need. But the price makes it inaccessible for the majority of people who could benefit from it.

Insurance coverage for Winlevi is inconsistent. Many plans require prior authorisation and step therapy — meaning you must try (and fail) cheaper treatments first before Winlevi is approved. Some plans don't cover it at all. The manufacturer offers a copay card for eligible commercially insured patients, but this doesn't help uninsured or underinsured patients. With no generic on the horizon (patent protection extends beyond 2030), the price barrier isn't going away soon.

The cost issue becomes even more significant when you consider that Winlevi is a maintenance treatment. Acne returns when you stop — just like with spironolactone. So you're not paying $500 once; you're paying $500 per month, indefinitely, to maintain results. At $5,000-6,000 per year, this prices out the vast majority of patients who could benefit from topical androgen blocking.

Winlevi vs Every Anti-Androgen: The Comparison

If your acne is hormonally driven, you have several anti-androgen options. Here's how they compare on the factors that actually matter for your decision.

The data pattern is clear: every anti-androgen option involves trade-offs between efficacy, cost, side effects, and accessibility. Winlevi has the best safety profile of any prescription option but the worst cost profile. Spironolactone has the strongest evidence but the most side effects. OTC topical approaches offer the best cost-to-accessibility ratio with no systemic effects, though they lack the FDA-approval stamp of Winlevi specifically.

Winlevi vs Spironolactone: Head to Head

This is the comparison most patients want. Both block androgen receptors. Both target the hormonal driver of acne. But the practical differences are enormous.

The choice often comes down to this: if cost is not a barrier and you want to avoid any systemic effects, Winlevi is the obvious choice. If you need proven efficacy for severe hormonal acne at an affordable price and can tolerate the side effects, spironolactone has decades more evidence. If you want the topical anti-androgen approach without the prescription or the price, an OTC topical androgen blocker gives you the same mechanism at a fraction of the cost.

Does Acne Come Back After Stopping Winlevi?

Yes. And this is the same pattern seen with every anti-androgen treatment — spironolactone, birth control, and now Winlevi.

Winlevi doesn't cure hormonal acne any more than spironolactone does. It manages it by occupying the receptor site. When you stop applying the cream, DHT regains access to the receptor, the oil gland reactivates, and the cystic breakout cycle returns. This is exactly the same recurrence pattern documented with oral spironolactone (80-85% relapse rate within 3-6 months).

This makes the cost calculation even more critical. Winlevi isn't a one-time investment — it's a monthly expense for as long as you want clear skin. At $500+ per tube per month, that's $6,000+ per year, indefinitely. Compare this to generic spironolactone ($120-360/year) or an OTC topical protocol ($828/year at $69/month, or $556/year with the 3-month package). The mechanism is the same across all three — the difference is cost and delivery.

The OTC Alternative: Same Mechanism, No Prescription

Winlevi's breakthrough wasn't the molecule — it was the validation of the concept. It proved to the FDA, dermatologists, and patients that topical androgen receptor blocking at the oil gland works for acne. The androgen receptor doesn't require clascoterone specifically — it responds to any molecule that competitively blocks DHT from binding.

This is the principle behind topical androgen blocking protocols that use natural and synthetic androgen receptor antagonists applied directly to the skin. The delivery is the same (topical, targeted at the sebaceous gland), the mechanism is the same (competitive receptor blocking), and the benefit is the same (reduced DHT-driven sebum production without systemic effects). The differences are: no prescription required, no $500/tube price, and a multi-step approach that also addresses bacterial biofilm and skin barrier repair — two factors Winlevi doesn't address at all.

For women with PCOS, the multi-target approach is particularly relevant because PCOS acne involves elevated androgens (addressed by receptor blocking), persistent biofilm (which is why cystic acne won't go away with single-target treatments), and a compromised skin barrier from years of aggressive treatment. Winlevi addresses only the first factor. A comprehensive protocol addresses all three.